Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Marco Fiorillo; Rebecca Lamb; Herbert B. B. Tanowitz; Anna Rita Rita Cappello; Ubaldo E. E. Martinez-Outschoorn; Federica Sotgia; Michael P. P. Lisanti

doi:doi:10.18632/aging.100983

← Back

Research Paper Volume 8, Issue 8 pp 1593—1606

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Figure 6. Bedaquiline augments glycolysis in normal human fibroblasts. The Seahorse XF96 analyzer was employed to determine the status of glycolysis in normal human fibroblasts treated with 10μM bedaquiline for 48 hours. (A) The line graph of 3 independent experiments is shown. (B, C, D, E) Glycolysis, glycolytic reserve, and ECAR were elevated. F. The plot of OCR versus ECAR shows that bedaquiline shifts the metabolic state of normal fibroblasts from a quiescent state to an energetic state. ** p<0.001.